Weight Loss Peptide Retatrutide Cagrilintide Survodutide Mt2 Ghkcu Peptide
TDS 148 Inquiries
49557-75-7
Pharmaceutical Grade
99.99%
Guangzhou
TOPI
10vials/box
2028-05-31
peptides,Semagiutide,Retatrutide,GHK-CU,MOTS-c,Semax
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceChEBI: Gly-His-Lys is a tripeptide composed of glycine, L-histidine and L-lysine residues joined in sequence. It has a role as a metabolite, a chelator, a vulnerary and a hepatoprotective agent.CertificatesBasic Info
-
Product Name:
Copper Peptide
Other Name:GHK Cu Copper Peptide;L-Lysine,glycyl-L-histidyl-;Copper Peptide powder (GHK-cu);GHK Cu Copper Peptide GHK.Cu GHK-Cu;Liver Cell Growth Factor(GHK);GHKcu/Growth-Modulating peptide;(Gly-His-Lys)2Cu.xHAc;AHK-Cu (Copper Peptide)
CAS No.:49557-75-7
Molecular Formula:C14H24N6O4
InChIKeys:MVORZMQFXBLMHM-QWRGUYRKSA-N
Molecular Weight:340.38
EC Number:1592732-453-0
Color/Form:Off-White
Categories:
Characteristics-
Density:
1.324
Melting Point:>144°C (dec.)
Boiling Point:831.0±65.0 °C(Predicted)
PKA:3.11±0.10(Predicted)
Critical Temperature & Pressure:under inert gas (nitrogen or Argon) at 2–8 °C
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
peptides,Semagiutide,Retatrutide,GHK-CU,MOTS-c,Semax
-
Location:
Units 1503-14, 15th Floor, New HNA Building, No. 7 Guoxing Avenue, Lantian Subdistrict, Meilan District, Haikou City, Hainan Province
-
Payment Terms:
TT against copy of documents,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
3
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
101-200
-
Year of Establishment:
2025
-
-
Inquiry History148 Inquiries
Country Product Purchase Quantity Date Posted
United States
Cosmetic Copper GhkCU Peptide CAS 49557-75-7 Peptide 50mg Ghk-Cu
2 MT Nov 6, 2023
Malaysia
High quality 98% up Copper Peptide GHK-Cu powder CAS 49557-75-7
1 KG Oct 19, 2023
United States
Copper Peptide 99% Copper Peptide Ghk-Cu Powder Ghk Cu CAS 49557-75-7
1 KG Mar 26, 2026
Sweden
GHK-Cu
1 KG Mar 17, 2026
China
Glycyl-l-histidyl-l-lysine
10 KG Oct 24, 2023
Germany
GHK CU
100 MG Aug 12, 2026
Australia
Copper peptide
1 MT Aug 10, 2026
Russia
GHK-Cu
50 MG Aug 6, 2026
United States
copper-peptide ghk-cu
20 MT Jul 26, 2026
Peru
GHK-Cu
15 MG Jul 13, 2026
United States
GHK-Cu
100 MG Jul 13, 2026
United States
GHK-Cu
1 G Jul 13, 2026
United States
GHK-CU
5 MT Jul 12, 2026
Malaysia
GHK-Cu
1 G Jul 9, 2026
South Africa
GHK-CU
3 MG Jun 17, 2026
United States
GHK-CU
1 MT Jun 13, 2026
United Kingdom
GHK-CU
5 KG Jun 11, 2026
Canada
Ghk-cu
500 MG Jun 11, 2026
Australia
GHK-Cu
1 G Jun 8, 2026
Thailand
GHK-CU
100 MG Jun 5, 2026 Post an enquiry for this product
